40 research outputs found
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women.
Antidepressants during and after Menopausal Transition: A Systematic Review and Meta-Analysis
To assess the therapeutic benefits of antidepressants in depressive women during and after menopausal transition, PubMed, Cochrane Library, EMBASE and Science Direct were systematically searched from inception to February 1, 2020 for randomized controlled trials examining antidepressants compared to placebo. Primary outcome was change in depressive symptom severity, while secondary outcomes were rates of response/remission rates and dropout/discontinuation due to adverse events. Seven trials involving 1,676 participants (mean age = 52.6 years) showed significant improvement in depressive symptoms (k = 7, Hedges’ g = 0.44, 95% confidence interval (CI) = 0.32 to 0.57, p < 0.001) relative to that in controls. Furthermore, response (k = 3, odds ratio (OR) = 2.53, 95% CI = 1.24 to 5.15, p = 0.01) and remission (k = 3, OR = 1.84, 95% CI = 1.32 to 2.57, p < 0.001) rates were significantly higher in antidepressant-treated groups compared to those with controls. Although dropout rates did not differ between antidepressant and control groups (k = 6, OR = 0.93, 95% CI = 0.70 to 1.26, p = 0.68), the rate of discontinuation due to adverse events was significantly higher in antidepressant-treated groups (k = 6, OR = 0.55, 95% CI = 0.35 to 0.86, p = 0.01). Subgroup analysis indicated that antidepressants were also efficacious for depressive symptoms in those without diagnosis of MDD. The results demonstrated that antidepressants were efficacious for women with depressive syndromes during and after menopausal transition but associated with a higher risk of discontinuation due to adverse events
Recommended from our members
Use of compounded hormone therapy in the United States: report of The North American Menopause Society Survey
Objective: A national survey was conducted to determine the extent of use of compounded hormone therapy
(C-HT) and to characterize the differences between C-HT users and users of hormone therapy approved by the US
Food and Drug Administration (FDA-HT users).
Methods: This Internet survey enrolled 3,725 women aged 40 to 84 years who were postmenopausal or
experiencing the menopause transition. The sample was weighted slightly by age, region, education, and race to
reflect population attributes based on US Census data.
Results: Overall, 9% of women were current users of HT, and 28% of all respondents were ever-users of HT.
C-HT users represented 31% of ever-users of HT, 35% of current users of HT, and 41% of ever-users aged 40 to 49
years. Approximately 13% of ever-users indicated current or past use of testosterone. The most cited reason for
using HT was vasomotor symptoms ( 70%). Nonapproved indications for using HT were selected more often by
C-HT users. There were four reports of endometrial cancer among the 326 C-HT users compared with none reported
among the 738 FDA-HT users. Significance was not determined because of small numbers.
Conclusions: This survey indicates substantial use of C-HT across the country and the possibility of higher rates
of endometrial side effects with such products. There is a need for standardized data collection on the extent of use of
compounded hormones and their potential risks